Travere Therapeutics Stock Alpha and Beta Analysis
| TVTX Stock | USD 19.73 0.60 3.14% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Travere Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Travere Therapeutics over a specified time horizon. Remember, high Travere Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Travere Therapeutics' market risk premium analysis include:
Beta 1.67 | Alpha 0.27 | Risk 3.8 | Sharpe Ratio 0.0711 | Expected Return 0.27 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Travere |
Travere Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Travere Therapeutics market risk premium is the additional return an investor will receive from holding Travere Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Travere Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Travere Therapeutics' performance over market.| α | 0.27 | β | 1.67 |
Travere Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Travere Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Travere Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Travere Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Travere Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Travere Therapeutics shares will generate the highest return on investment. By understating and applying Travere Therapeutics stock market price indicators, traders can identify Travere Therapeutics position entry and exit signals to maximize returns.
Travere Therapeutics Return and Market Media
The median price of Travere Therapeutics for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 19.27 with a coefficient of variation of 9.67. The daily time series for the period is distributed with a sample standard deviation of 1.9, arithmetic mean of 19.61, and mean deviation of 1.58. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 2066 shares by Inrig Jula of Travere Therapeutics at 19.1 subject to Rule 16b-3 | 01/03/2025 |
2 | Disposition of 440 shares by Inrig Jula of Travere Therapeutics at 18.76 subject to Rule 16b-3 | 01/06/2025 |
3 | Disposition of 925 shares by Sandra Calvin of Travere Therapeutics at 18.9408 subject to Rule 16b-3 | 01/22/2025 |
4 | Disposition of 16000 shares by Baynes Roy D. of Travere Therapeutics at 17.5 subject to Rule 16b-3 | 01/23/2025 |
5 | Vanguard Group Inc Reduces Stake in Travere Therapeutics Inc | 01/31/2025 |
6 | Disposition of 3348 shares by Sandra Calvin of Travere Therapeutics at 20.12 subject to Rule 16b-3 | 02/03/2025 |
7 | Disposition of 1066 shares by Inrig Jula of Travere Therapeutics at 20.11 subject to Rule 16b-3 | 02/04/2025 |
8 | Disposition of 8000 shares by Inrig Jula of Travere Therapeutics subject to Rule 16b-3 | 02/10/2025 |
9 | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 02/12/2025 |
10 | Travere Therapeutics Q4 2024 Earnings Preview | 02/19/2025 |
11 | Travere Therapeutics Non-GAAP EPS of -0.47 misses by 0.09, revenue of 74.79M beats by 2.41M | 02/20/2025 |
12 | Travere Therapeutics Inc Q4 2024 Earnings Call Highlights Strong Phil Spari Sales and ... | 02/21/2025 |
13 | Travere Therapeutics Inc Announces Participation in Upcoming Investor Conferences | 02/25/2025 |
14 | JPMorgan Chase Co. Increases Travere Therapeutics Price Target to 44.00 | 02/28/2025 |
15 | Disposition of 8951 shares by Elizabeth Reed of Travere Therapeutics at 19.78 subject to Rule 16b-3 | 03/03/2025 |
16 | Travere Therapeutics Tricky Outlook Gives Me Pause For Thought - Downgrade - Seeking Alpha | 03/07/2025 |
17 | Acquisition by Peter Heerma of 8000 shares of Travere Therapeutics subject to Rule 16b-3 | 03/12/2025 |
18 | Acquisition by Sandra Calvin of 26000 shares of Travere Therapeutics at 20.46 subject to Rule 16b-3 | 03/13/2025 |
About Travere Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Travere or other stocks. Alpha measures the amount that position in Travere Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 0.44 | 0.27 | 0.25 | 0.3 | Days Of Inventory On Hand | 332.79 | 299.97 | 344.96 | 437.62 |
Travere Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Travere Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Travere Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Travere Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Travere Therapeutics. Please utilize our Beneish M Score to check the likelihood of Travere Therapeutics' management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Travere Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.